C4T Collaborates with Roche on Innovative Cancer Therapies
C4 Therapeutics has entered a partnership with Roche to develop degrader-antibody conjugates that promise to improve cancer treatment outcomes. This collaboration includes a $20 million upfront payment and potential milestone payments exceeding $1 billion, enhancing C4T's financial position and growth prospects in the oncology space.
View signal analysis